Core Viewpoint - Guangdong Province's Medical Insurance Bureau has announced the optimization and integration of medical service pricing for dialysis, ultrasound, and traditional Chinese medicine, ensuring that the financial burden on dialysis patients does not increase [1][2]. Group 1: Dialysis Service Pricing - The previous 32 items related to "machine-assisted plasma exchange" have been consolidated into 21 items under "blood dialysis fees," with a provincial maximum price set at 390 yuan per session, covering all necessary procedures and resources [2]. - The maximum price for peritoneal dialysis (manual) is set at 45 yuan per session, while automated peritoneal dialysis is priced at 16 yuan per hour [2]. - Public medical institutions must charge according to the integrated pricing for dialysis services and cannot charge separately for different components of the service [2][3]. Group 2: Traditional Chinese Medicine and Ultrasound Pricing - The previous 60 items for "ordinary acupuncture" have been consolidated into 10 pricing items for acupuncture methods, while 105 items for "fracture manual reduction" have been reduced to 9 items for orthopedic methods [4]. - The pricing for ultrasound services has been streamlined from 84 items to 13, with ultrasound report services now included in the ultrasound pricing, eliminating separate charges for reports [4]. - The maximum prices for the newly integrated services must not exceed the provincial limits, with local prices allowed to be lower [4].

Core Viewpoint - The steady growth of the Chinese economy and its commitment to medical innovation are crucial drivers shaping the future of the global industry [1][2] Group 1: Company Overview - Wan Yi Te is a significant organ therapy company with a product line that includes peritoneal dialysis, hemodialysis, and critical care treatment [1] - Since entering the Chinese market in 1989, Wan Yi Te has established a complete industrial chain covering R&D, manufacturing, sales, and services [1] - The company has its China headquarters in Shanghai, with a world-class R&D center and production bases in Suzhou, Guangzhou, and Tianjin [1] Group 2: Market Insights - The Chinese market is a vital pillar of Wan Yi Te's global strategy, being the second-largest medical device market in the world [2] - There is a significant demand for high-quality medical health services and personalized treatment options among the Chinese population [2] - Favorable policies in digital healthcare, home treatment, and chronic disease management align with Wan Yi Te's mission to enhance patient care and treatment efficiency [2] Group 3: Future Directions - Wan Yi Te aims to seek more collaboration opportunities in China, believing that strong local partnerships can leverage advantages and embrace changes in the medical field [3]